Additionally, the 36-month beta value for IBIO is 0.96. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for IBIO is 15.58M and currently, short sellers hold a 4.07% ratio of that float. The average trading volume of IBIO on June 13, 2025 was 1.10M shares.
IBIO) stock’s latest price update
The stock price of iBio Inc (NASDAQ: IBIO) has jumped by 7.22 compared to previous close of 0.96. Despite this, the company has seen a gain of 11.17% in its stock price over the last five trading days. globenewswire.com reported 2025-05-05 that SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) — iBio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced new promising preclinical data for its first-in-class Activin E antibody unveiled in January. Data from the recently completed 4-week study in diet-induced obese mice show a 26% reduction in fat mass following treatment with the Activin E antibody, with muscle mass fully preserved. These findings highlight a significant fat loss can be achieved without the double-digit weight reductions typically required by other obesity drugs.
IBIO’s Market Performance
IBIO’s stock has risen by 11.17% in the past week, with a monthly rise of 28.75% and a quarterly drop of -79.92%. The volatility ratio for the week is 6.17% while the volatility levels for the last 30 days are 5.66% for iBio Inc The simple moving average for the past 20 days is 20.38% for IBIO’s stock, with a -59.11% simple moving average for the past 200 days.
Analysts’ Opinion of IBIO
Many brokerage firms have already submitted their reports for IBIO stocks, with Chardan Capital Markets repeating the rating for IBIO by listing it as a “Buy.” The predicted price for IBIO in the upcoming period, according to Chardan Capital Markets is $5 based on the research report published on May 28, 2024 of the previous year 2024.
JMP Securities, on the other hand, stated in their research note that they expect to see IBIO reach a price target of $1.50. The rating they have provided for IBIO stocks is “Mkt Outperform” according to the report published on November 29th, 2021.
Cantor Fitzgerald gave a rating of “Overweight” to IBIO, setting the target price at $3 in the report published on January 22nd of the previous year.
IBIO Trading at -5.81% from the 50-Day Moving Average
After a stumble in the market that brought IBIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -85.05% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IBIO starting from Duran Felipe, who purchase 9,191 shares at the price of $2.72 back on Jan 10 ’25. After this action, Duran Felipe now owns 11,139 shares of iBio Inc, valued at $25,000 using the latest closing price.
Brenner Martin, the of iBio Inc, purchase 9,191 shares at $2.72 during a trade that took place back on Jan 10 ’25, which means that Brenner Martin is holding 18,316 shares at $25,000 based on the most recent closing price.
Stock Fundamentals for IBIO
Current profitability levels for the company are sitting at:
- -44.83 for the present operating margin
- 2.98 for the gross margin
The net margin for iBio Inc stands at -55.98. The total capital return value is set at -1.23. Equity return is now at value -90.83, with -47.53 for asset returns.
Based on iBio Inc (IBIO), the company’s capital structure generated 0.2 points at debt to capital in total, while cash flow to debt ratio is standing at -5.3. The debt to equity ratio resting at 0.26. The interest coverage ratio of the stock is -73.74.
Currently, EBITDA for the company is -14.02 million with net debt to EBITDA at 0.14. When we switch over and look at the enterprise to sales, we see a ratio of 39.97. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.12.
Conclusion
In conclusion, iBio Inc (IBIO) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
